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Abstract: The ability to specifically block or degrade cytosolic targets using therapeutic proteins
would bring tremendous therapeutic opportunities in cancer therapy. Over the last few years, sig-
nificant progress has been made with respect to tissue targeting, cytosolic delivery, and catalytic
inactivation of targets, placing this aim within reach. Here, we developed a mathematical model
specifically built for the evaluation of approaches towards cytosolic protein delivery, involving all
steps from systemic administration to translocation into the cytosol and target engagement. Focusing
on solid cancer tissues, we utilized the model to investigate the effects of microvascular perme-
ability, receptor affinity, the cellular density of targeted receptors, as well as the mode of activity
(blocking/degradation) on therapeutic potential. Our analyses provide guidance for the rational opti-
mization of protein design for enhanced activity and highlight the importance of tuning the receptor
affinity as a function of receptor density as well as the receptor internalization rate. Furthermore,
we provide quantitative insights into how enzymatic cargoes can enhance the distribution, extent,
and duration of therapeutic activity, already at very low catalytic rates. Our results illustrate that
with current protein engineering approaches, the goal of delivery of cytosolic delivery of proteins for
therapeutic effects is well within reach.
Keywords: binding-site barrier; drug delivery modelling; cytosolic protein delivery; peptide delivery;
targeted protein degradation; cancer therapy
1. Introduction
In comparison to the rapid growth of the arsenal of protein-based therapies targeting
extracellular receptors, the development of therapies in which proteins address an intracel-
lular target lags far behind. Only three have been approved so far: the recombinant im-
munotoxins denileukin diftitox (Ontak), tagraxofusp, and moxetumomab pasudotox [1–3].
All act by delivering catalytic protein domains that block protein synthesis. These isolated
examples made it into the clinic because they combine an extremely high potency with rel-
atively well-accessible targets in T cell lymphomas and B cell leukemias. This particular set
of properties is shared with many more similar agents currently in clinical development [4].
In contrast, few therapeutic proteins acting inside the cell are far in development for solid
tumors or other diseases in which cells in a tissue need to be reached [4].
Beyond recombinant immunotoxins, there are ample potential applications for cytoso-
lically delivered proteins that can be divided into those that (temporarily) add a function
and those that block a pathway as inhibitors. Examples for the former include the de-
livery of enzymes [5] or proteins that reprogram or genetically modify cell populations
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in vivo [6,7]. The latter can be achieved either via direct protein inhibition or, as has at-
tracted more attention recently, through enzymatic target modification, which, for instance,
was achieved for RAS oncoproteins [8]. It can, in principle, also occur via targeted protein
degradation [9], although in vivo targeted protein degradation using engineered proteins
has not yet been reported. Blocking type applications can be especially powerful for cancer
therapies or senescent cell removal, where blocking a pathway can drive cells that rely on
this pathway for survival into apoptosis. Through binding of large interaction surfaces,
proteins can easily mediate levels of specificity and modes of activity that are very diffi-
cult if not impossible to achieve with small molecules [10], thus massively expanding the
druggable genome [11].
During the last years, there has been a steady development of approaches to deliver
proteins into the cytosol of cells cultured in 2D in vitro systems [12–15]. However, there
has been little success to translate these results into activity in vivo. Due to its challenges,
access of therapeutic proteins to intracellular targets has been referred to as “high-hanging
fruit”: highly desirable, but difficult to achieve [16].
This lack of progress may be attributed to the fact that in vivo protein delivery to
cells that reside outside of the bloodstream presents several additional challenges. These
challenges include extravasation in the organ of interest, adequate penetration into the
tissue, and accumulation at the target cells [17]. For cytosolic delivery, as opposed to
endosomal delivery, there additionally needs to be a moiety that enables the protein to
escape endosomes; for instance, an endosomal escape peptide or a bacterial translocation
domain [18]. Currently, there are several excellent computational models available that
can be used to simulate the delivery of agents that bind to extracellular targets or to
tumor tissues in general [19,20]. In contrast, in-depth modeling approaches to understand
and define the requirements to yield effective cytosolic protein delivery for therapeutic
applications have, to the best of our knowledge, not yet been reported.
Here, we present a mathematical model specifically built for the evaluation of protein
engineering approaches directed at cytosolic protein delivery in in vivo solid tumor tissues.
We employ this model to investigate how microvascular permeability, molecular size,
affinity for a cellular target receptor, density of targeted receptors, and finally, mode of
action, influence the drug activity. We focused our investigations on solid tumors, while
reflecting on the consequences for protein-based therapeutics in various therapeutic areas.
Our results demonstrate that for cytosolic protein delivery for a given area of application,
in vivo activity can be rationally optimized through the proper tuning of parameters that
are readily controllable through protein engineering and/or proper dosing regimes.
2. Materials and Methods
A technical explanation of the model, outcome parameters, as well as the rationale for
the choice of input parameters and model assumptions is provided as a Supplementary
Materials section.
3. Results
3.1. Modeling Protein Delivery
To generate a quantitative understanding of the requirements for effective in vivo
cytosolic protein delivery, we developed a mathematical model incorporating key elements
of cellular targeting, entry, and intracellular activity. The model was, in part, inspired by
work from Thurber et al., in which antibody delivery in vivo was described within a Krogh
geometry consisting of two concentric cylinders; the inner cylinder represented a capillary,
and the outer represented the surrounding tissue (Figure 1) [19]. The model permits the
in silico evaluation of all physical and biological phenomena that we reasoned would
significantly influence cytosolic protein delivery and its therapeutic effects. Those param-
eters that relate to the engineered protein are size, affinity, intracellular binding, plasma
half-life, half-life in the cytosol, as well as the effects of enzymatic target modification on
the levels of functional cytosolic target proteins. Those parameters that relate more to the
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targeted tissue are vascular permeability, interstitial diffusivity, cellular internalization
rates, and cytosolic delivery efficiency (Figure 1). An extensive description of how the
model was designed and the rationale for the choice of all parameters is provided in the
Supplementary Materials section. As a representative tissue, we focused on solid tumors
of the breast overexpressing the tumor marker epithelial cell adhesion molecule (EpCAM),
while in some instances, we used normal skeletal muscle tissue for comparison. We made
a distinction between tumors that exhibited convection, i.e., those with functional lymph
vessels, and those that did not, and therefore exhibited little or no fluid flow and where
macromolecule transport is driven by diffusion. Results are, in most cases, described as
the degree of inhibition as a function of time (i.e., inhibition of a cytosolic target protein),
maximum inhibition (i.e., single time-point across the entire tissue), or as an inhibitory
effect (effect integrated over time and entire tissue). A technical explanation of how these
terms were calculated is given in the Supplementary Materials.
Figure 1. Schematic representation of protein delivery in vivo. Visualization of steps required
for achieving cytosolic protein delivery in vivo in tumor tissue. (1) Extravasation; (2) transport
in the interstitium; (3) binding to the cell surface; (4) internalization; (5) receptor recycling and
synthesis; (6) endosomal escape; (7) binding of cytosolic target. The model contains six partial
differential equations describing the changes in (i) the free therapeutic protein in the interstitium; (ii)
the unbound cell surface receptor; (iii) the surface complex of receptor and therapeutic protein; (iv)
the free therapeutic protein delivered to the cytosol; (v) the free cytosolic target protein; and finally,
(vi) the inhibitory complex of therapeutic protein and cytosolic target. The bar in the upper-left
corner shows the color scheme that represents the concentration of therapeutic protein delivered into
the tissue. A complete mathematical description and a full explanation of its workings is given in the
Supplementary Materials.
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3.2. Simulation of Delivery and Therapeutic Effects In Vivo
We initially simulated delivery of a protein with a molecular weight of 70 kDa binding
to the tumor marker EpCAM. Binding properties were taken from the designed ankyrin
repeat protein (DARPin) Ec1, which binds EpCAM with an affinity (Kd) of 68 pM [21].
We assumed a tumor tissue containing a cell density of 2.9 × 108 cells/mL, representing
a tumor with a high cellularity, and a receptor density of 5.4 × 105 receptors/cell, which
we previously determined for EpCAM on MCF-7 cells [22]. As indicated above, we
thus considered the tissue as a homogenous medium in which cellular structures are
not explicitly defined. We simulated a starting protein plasma concentration of 1 µM,
a concentration that can be realistically reached upon intravenous administration of a
therapeutic protein [23] (Figure 2A). A sharp decline in the delivered protein concentration
away from the capillary was observed, with the majority of protein being confined to
the first 20 µm of tissue. When an EpCAM binder is combined with a moiety or vector
that mediates efficient cytosolic delivery, e.g., an endosomal escape peptide or a bacterial
toxin-derived translocation domain as we reported previously [24] (see Supplementary
Table S2 for detailed information on assumptions), the simulated degree of target inhibition
(see Supplements for a technical explanation) varies across different distances from the
capillary (Figure 2B) and directly reflects protein delivery (Figure 2A), with maximum
inhibition in the tissue reached at around 24 h (Supplementary Video S1).
We then evaluated the maximum cytosolic delivery and inhibition with a targeted
protein (Figure 2C,D) or a targeted peptide (Figure 2E,F) in tumors with and without
convection and compared it with delivery in normal tissue (skeletal muscle was chosen
as a representative tissue because of the availability of experimental values of needed
parameters in the literature). The relevant difference between both types of compounds
is size, and we modelled a molecular weight (MW) of 3.5 kDa for the peptide, which is
the MW of the calcitonin peptide hormone. Calcitonin is a medically used peptide for
which half-lives have been determined in vivo in humans [25] (Supplementary Table S3).
Employing a targeted peptide resulted in more rapid clearance but also faster penetration
due to a higher interstitial diffusivity. We also included peptides because for this class of
compounds, several strategies for cytosolic delivery have been described. For both proteins
and peptides, cytosolic delivery and inhibition in tumors vastly surpassed that achieved in
muscle tissue in terms of tissue reached, mostly due to the enhanced permeability of leaky
blood vessels. Convection additionally contributed substantially to an enhanced depth of
penetration for proteins (Figure 2C).
While targeted proteins were delivered in high concentrations to the tissue imme-
diately adjacent to the capillary but rapidly decreased in concentration further away,
peptides permeated the entire tissue more evenly by comparison, although in lower levels
(Figure 2C,E).
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Figure 2. Radius of simulated delivery and biological effects of targeted agents in tumor tissue. (A) Simulation of radial and
time-dependency of delivery of a model protein (70 kDa, target affinity: 68 pM) in tumor tissue without convection. Lines
represent different timepoints shown up to the point of maximum delivery (24 h for protein). Supplementary Video S1
shows timepoints until 72 h for protein. We simulated a plasma half-life of 2.55 h, the half-life of the 83 kDa therapeutic
enzyme laronidase [26], and modelled 5.3 × 105 receptors/cell, as described for EpCAM on MCF7 cells [22]. (B) Depiction
of the number of free cytosolic target proteins for the situation where an inhibitory target-binding protein is delivered under
the same conditions as in (A). A total of 10,000 target molecules/cell were modelled, which is close to the mean level in
eukaryotic cells as based on proteomic analyses [27]. Supplementary Figure S1 shows similar graphs as (A,B) for a model
peptide. (C) 70 kDa model protein delivery (as in A) as a function of the distance from the lumen of the nearest blood vessel
(radius) at the time-point of maximum delivery for distinct conditions. (D) Free target protein in tumor tissue compared
to normal skeletal muscle tissue as a function of distance from the nearest blood vessel under conditions as in (C). (E,F).
Same as for (C) and (D), but for a model 3.5 kDa targeted peptide. For the peptide, a half-life of 0.28 h was simulated, as
reported for the therapeutic peptide calcitonin [25]. Time of maximum delivery for peptide is 17 h (vs. 24 h for protein).
For detailed model assumptions, their rationale, and a technical explanation of the outcome terms on the y-axes, see the
Supplementary Materials.
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3.3. Effect of Receptor Affinity on Peptide and Protein Delivery
The binding-site barrier is a phenomenon where high-affinity targeted agents bind
tightly to receptors in the first cell layers encountered and only travel further into the
tissue upon receptor saturation. The affinity for receptors, the receptor density, and the
receptor internalization rate are well-established factors with respect to the binding-site
barrier [19,28,29], although quantitative insights into the impact of the binding-site barrier
on tissue penetration under different conditions are lacking. One approach to minimize
the negative consequences of the binding-site barrier is to modulate the affinity of a
targeted agent towards its cellular receptor. Importantly, a lower affinity may benefit tissue
penetration. First, we determined the optimum receptor affinity for tumor targeting with
or without convection for a fixed receptor density for both targeted proteins and peptides
(Figure 3), as determined by maximal delivery to the tissue. Maximal delivery was defined
as the situation when the average concentration across the tissue of the free target protein
was at its lowest.
Figure 3. The dependency of delivery of proteins and peptides to tumors on receptor affinity. (A) The effect of affinity on
inhibition by a targeted protein (70 kDa) (left y-axis) for tumor tissues with 5.3 × 105 receptors per cell, and for a healthy
control tissue (skeletal muscle), with 10× (1/10) and 100× (1/100) lower receptor levels. Dots identify the datapoints
corresponding to individual simulations. The right y-axis shows a histogram of the relative frequency of protein interactions
in the KOFFI database with their affinities per order of magnitude [30]. The KOFFI database collects binding kinetics data
from biomolecular interactions from the literature. (B) Same as (A), but for targeted peptides.
Convection facilitates the rapid transport of macromolecules from the immediate
proximity of the endothelium deeper into the tissue, and its effect on protein delivery was
therefore of particular interest. We found that higher affinities for targeted proteins were
needed for the optimal delivery in tumors without convection. The presence of convection
in tumors greatly reduced the optimal affinity and enhanced the overall therapeutic effect
(Figure 3A).
For peptide delivery, on the other hand, almost identical optimal affinities were
observed in the presence or absence of convection, and delivery only mildly increased in the
presence of convection. When comparing peptides vs. proteins, peptides produced superior
delivery in tumors without convection due to the higher permeability and diffusivity, while
proteins surpass peptides in tumors with convection due to their longer plasma half-life
(see also Figure 2C,E). The steeper decline in delivered molecules observed for proteins vs.
peptides indicates a more pronounced binding-site barrier for slower-diffusing proteins.
Targeted proteins can easily be engineered to be highly selective and have affinities that
are considered optimal by our modeling approach (Figure 3A). However, for peptides, the
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ability to obtain high affinities appears to be a limiting factor for their efficacy (Figure 3B),
although peptides with very high affinities have been reported [30], including peptides
that bind with subnanomolar Kd values to vascular endothelial growth factor (VEGF)
receptor 2 and c-MET, or hapten peptides that bind to single chain variable fragments with
affinities as high as 2.3 nM [31]. Interestingly, for targeted proteins, the optimal affinities
for targeting tumors with and without convection, of 16.4 nM and 625 pM, respectively,
for these simulated parameters, appear to be readily achievable, as demonstrated by the
superimposition of the frequency distribution of protein affinities reported in the literature
and compiled in the kinetics database KOFFI [30].
When investigating the effect of receptor density for our default conditions (i.e.,
using a proteinaceous EpCAM binder with an affinity of 68 pM), we noted a very strong
dependency of the therapeutic effect on the receptor density (Supplementary Figure S3).
This mirrors the effects of modulating receptor affinity (see Figure 3A) and reflects the
characteristics of the binding-site barrier. Therapeutic effects were highest at around
1–2 × 105 receptors/cell (Supplementary Figure S3).
3.4. Interplay Between Receptor Affinity, Receptor Density and Internalization Rate
At present, we are not aware of reports that relate the optimal affinity to receptor
density and the receptor internalization rate. Ultimately, this knowledge may guide the
choice of suitable receptors for targeting in the development of cancer therapies. Next to
target affinity and receptor density, the internalization rate of cellular receptors plays
a prominent role in determining the properties of the binding-site barrier [29]. This
is illustrated by determining the affinity that yields the greatest therapeutic effect (i.e.,
optimum affinity) as a function of receptor density for receptors that differ in internalization
rates, either in the presence or absence of convection (Figure 4A). Although internalization,
recycling rates, and even trafficking routes for receptors can differ as a function of the ligand
utilized for targeting (e.g., natural ligands vs. engineered binders), as well as the epitope
addressed on a specific receptor, our simulations indicated that receptors which generally
internalize faster, e.g., epidermal growth factor receptor (EGFR), necessitate a lower optimal
affinity for maximal tissue delivery. Again, convection decreased the optimal affinity for
delivery for all internalization rates and also increased the internalization rate-dependent
differences (Figure 4). In our model, we simulated steady state levels of receptors by
matching the rate of internalization with the rate of recycling, thus mimicking the delivery
of non-toxic proteins (for details, see the Supplementary Materials). A fraction of targeted
agents was delivered to the cytosol in the model, with the rest being degraded. Even in the
presence of a moiety that mediates endosomal escape, degradation in the endolysosomal
system is a common fate of endocytosed proteins, and only a fraction of internalized protein
reaches the cytosol [18]. Remarkably, for a binder exhibiting the optimal affinity, the same
overall magnitude of delivery and inhibition can be achieved largely irrespective of the
receptor density and internalization rate (Figure 4B). This implies that targeting should not
only focus on those receptors which are present at very high levels and for which very high
affinity binders are available, which would increase the options for productive targeted
drug delivery.
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Figure 4. Optimal receptor affinities for overcoming the binding-site barrier. (A) Optimal receptor affinity in terms of overall
delivery as a function of receptor density in tumors containing convection and those that do not for three reported rates
of receptor internalization (ke). EGFR: ke = 0.08 min−1 [32]; HER2: 0.01 min−1 [32]; EpCAM: 0.002 min−1 [33]. Of note,
internalization rates can differ substantially as a function of the ligand used for targeting. (B) Maximum inhibition achieved
by optimizing receptor affinity for different receptor densities in tumor. Data correspond to datapoints seen in Figure 4A.
(C) Heatmap showing the maximum inhibition produced by targeting a receptor with a reported internalization rate of
HER2, at widely different expression levels, with targeted agents of varying affinities, in a tumor lacking convection.
(D) Same as (C), but in a tumor with convection. Heatmaps for EpCAM and EGFR are shown in Supplementary
Figure S4. For detailed model assumptions and a technical explanation of the outcome terms on the y-axes, see the
Supplementary Materials.
Nonetheless, specificity and potential off-target effects should always be taken into
consideration. Notably, for diffusion-based delivery, maximal delivery is always lower,
emphasizing the relevance of convection in targeted delivery to tumors.
3.5. Effect of Cold Dosing, Targeted Protein Degradation and Degradation-Resistant Proteins on
the Binding-Site Barrier
As illustrated by our analyses so far, protein targeting deep into tissues faces several
dilemmas. Small size, on the one hand, favors penetration, but on the other hand, leads to
faster clearance. A high receptor affinity promotes effective cellular targeting, although lim-
its penetration due the rapid capture of extravasated proteins by the first layer of cells, also
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referred to as the binding-site barrier. As an approach to overcome the binding-site barrier,
cold dosing, where the therapeutic moiety is only present on a fraction of administered
targeted agents, has been investigated for a long time. Mostly, this has been performed
in the context of radiolabeled antibody [34,35] but, more recently, also in the context of
antibody–drug conjugates [36,37]. In addition, there are multiple protein engineering
approaches aimed to enhance intracellular delivery and/or subsequent therapeutic effects,
some of which are only recently coming to the fore for engineered proteins. The therapeutic
potency can be increased without affecting delivery itself, through either delivery of (target
protein-inactivating) enzymes [8,38], targeted protein degradation [39], or by enhancing
the stability of the delivered agent against proteasomal degradation [40,41].
In our simulations, catalytic inactivators represent both enzymes that inactivate target
proteins and protein-based agents that induce target protein degradation, because for both
types of activities, the functional outcome is the same. Given our assumptions (see Supple-
mentary Materials), catalytic agents strongly outperform binders whose effect is limited
to inhibition by direct blockade of the protein—protein interaction, in particular at lower
concentrations (Figure 5A) or when the target protein concentration is high (Figure 5B). For
instance, at a target protein level of 1.0 × 105 molecules/cell and using catalytic inactivators,
a very strong and pronounced inhibition can be observed as compared to inhibition by
binding only (Figure 5B). Irrespective of the presence of a binding-site barrier, the high
activity upon cytosolic delivery of even small amounts of catalytic inactivators results in
much stronger therapeutic effects throughout the tissue (Figure 5A,B). Assuming identical
delivery properties and stabilities in the cytosol, the effects are much longer-lasting, be-
cause after removal of the inactivator, the pool of target proteins first has to be replenished
by translation (Figure 5B). Even with relatively low estimates of rates of inactivation (low
kcat values), the effects are remarkably potent (Figure 5A).
Enhanced effects of catalytic cargoes can be further increased by repeated dosing
approaches. For a scenario with application of a dose resulting in a 200 nM concentration
of an enzymatic cargo in the plasma approximately every 4.5 days, greater therapeutic
effects are produced as compared to the twice-daily administration of binders to a plasma
concentration of 1 µM (Figure 5C). In a clinical setting, the lower plasma exposure required
for catalytic agents (Figure 5D) might have considerable benefits with respect to eliciting
non-specific side effects as well as immunogenic reactions [42]. We subsequently inves-
tigated the effect of cold dosing and analyzed the influence of the time interval between
warm and cold dose in tumors exhibiting convection and those that do not. Cold dosing
enhanced the overall inhibitory (i.e., therapeutic) effect, with stronger effects in tumors
exhibiting convection and in the presence of shorter time intervals (Figure 5E). Of note is
that for binders that show optimal receptor affinities, cold dosing tends to have little effect
(see below; Figure 5G).
As alluded to before, an alternative approach to increase the activity of proteins
delivered to the cytosol is to enhance the stability against degradation, for instance, by
removing lysine residues on the protein surface, through which the canonical pathway
of ubiquitination and proteasomal degradation occurs [43]. Alternatively, the (partial)
use of D-amino acids can improve stability [40,41], because protein stretches composed
of D-amino acids are resistant to proteolytic degradation. A higher cytosolic stability
was simulated as a longer cytosolic half-life of binders in our model (Figure 5F). Our
findings indicate that a moderate enhancement of the cytosolic half-life (4×) can make
the therapeutic effect much longer lasting. By contrast, a large increase in half-lives
(40×/100×) shows limited additional effects due to the constant synthesis of new target
proteins. Conversely, shortening the half-life cuts down the duration of the therapeutic
effect, although the maximum level of inhibition (i.e., at a single time-point) is surprisingly
unaffected even when a 10-fold shorter cytosolic half-life is assumed (Figure 5F).
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Figure 5. Strategies to overcome the binding-site barrier and prolong target inhibition in tumor tissue. (A) Simulation
of therapeutic effects of a single dose, yielding an initial plasma concentration given on the x-axis of a targeted protein
with an enzymatic cargo with different catalytic rate constants. The level of target protein in the cytosol was simulated to
be 1 × 105 per cell. (B) Effect over time for a dose corresponding to an initial plasma concentration of 1 µM of inhibitory
binding proteins or catalytic inactivators for different levels of target protein present in the cytosol. (C) Effect of dosing
regimens for binders and catalytic inactivators for 1 × 104 and 1 × 105 target molecules/cell. (D) Overall plasma exposure
for the dosing regimens in (C). (E) Effect of cold dose on inhibitory effects in tumors containing convection and those that
do not. (F) Effect of varying the half-life of delivered proteins in the cytosol on the inhibition. (G) Inhibitory effect of a single
dose yielding an initial plasma concentration of 1 µM in tumors with/without convection. In the case of cold dosing: the
cold dose had the same plasma concentration profile as the warm dose but no therapeutic cargo and a reduced size (10 kDa).
Default conditions as in Figure 2A were used, unless specified otherwise. Cyto t1/2 × 100 indicates a 100× longer half-life
in the cytosol of the targeted agent. For detailed model assumptions and a technical explanation of the outcome terms on
the y-axes, see the Supplementary Materials.
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When comparing strategies side-by-side, an optimization of receptor affinity was
more powerful than cold dosing with respect to maximizing effects throughout the tissue
(Figure 5G). When investigating the maximum inhibition instead of the inhibitory effect
achieved by these different strategies, the efficacy of a cold dose in tumors with convection
is strong when the affinity is not optimal, but has no positive effects when an optimal Kd
is modelled (Supplementary Figure S5). Extending the cytosolic half-life is, within the
conditions tested, ineffective with respect to increasing the level of maximum inhibition.
4. Discussion
The ability to deliver proteins efficiently into the cytosol of specific cells in vivo would
enable numerous novel therapeutic opportunities [16], including the interference with
signaling pathways in cancer and senescent cells, the restoration of missing functions in
genetic diseases, and potentially even the ability to reprogram cells in vivo to restore or
redirect their identity [44]. Here, we built a mathematical model for investigating the chal-
lenges of protein delivery in vivo and to evaluate the merit of engineering approaches that
are geared towards overcoming these challenges. As we demonstrate, the results provide
clear guidelines for protein engineers on how to design proteins more rationally towards
specific applications. While our quantitative analyses are focused on cancer targeting
in vivo, the findings are also qualitatively pertinent to other disease areas. Furthermore,
variants of the model can be employed to study protein transport and activity in microflu-
idic models mimicking the tumor microenvironment with various degrees of complexity,
and we are actively pursuing this line of research.
As a starting point, it is useful to consider that approaches that report cytosolic protein
delivery in 2D systems in vitro often report values of cytosolic concentrations for the de-
livered protein that are comparatively high (mid- or high-nanomolar range) [18,24,45–54],
which is well over the average level of molecules of a specific protein in a cell, which is
around 2000–8000 molecules/cell (~2–10 nM) [27]. Hence, addressing cytosolic targets
in vitro is already possible for some applications. However, similarly to challenges associ-
ated with a homogenous delivery to targeted agents to extracellular receptors [55], delivery
challenges and a rapid degradation in the cytosol imply that reaching these levels and
concomitant biological effects in vivo remains very difficult.
The binding-site barrier is an often-mentioned factor that limits effective tissue pene-
tration [28,56]. While it has long been known that reducing the affinity of a binder for a
specific receptor may facilitate tumor penetration [57], our simulations indicate that tuning
the receptor affinity for a particular receptor density, receptor internalization rate, and
the presence or absence of convection can be very powerful in increasing targeting. For
our default scenario (agent binding EpCAM with 68 pM), we observed a 16% increase in
maximum inhibition in tumors without convection and a 118% increase in tumors with
convection. The 16% increase in tumors without convection is modest because our starting
affinity was fairly close to the optimal affinity already (which was 625 pM), although in
general, improvements in tissue delivery by optimizing affinity surpass those achieved by
cold dosing approaches. Two notable outcomes of our simulations are (i) that the optimal
affinity for delivery is much lower in tumor tissue exhibiting convection compared to its
counterpart without convection, with optimal affinities differing between one and three
orders of magnitude, depending on the receptor internalization rate and receptor density
(Figure 4); and (ii) that within a large range of receptor internalization rates and receptor
densities, equal overall therapeutic effects can be accomplished, provided the affinity for
the receptor has been optimized (Figure 4).
With contemporary screening and protein engineering approaches, the tuning of affini-
ties is a feasible undertaking. Nevertheless, in practice, a balance needs to be found between
the optimal affinity for a specific set of conditions (e.g., type of receptor, receptor density,
convection) and the degree of heterogeneity in the tumor—often, tumors are characterized
by regions that differ in extracellular matrix (ECM) densities, in the presence of convective
flow [58,59], and in levels of receptor expression. As a consequence, heterogeneous delivery
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is often observed in antibody-treated tumors [60], and this heterogeneity is even more
pronounced when utilizing antibody–drug conjugates that already have dose-limiting
toxicities at low doses [36]. Our analyses on the interplay between the various factors that
govern cellular delivery (receptor density, internalization, affinity, convection) will aid the
understanding of the impact of heterogeneity on delivery. While tumor heterogeneity is an
inherent and challenging aspect of tumor targeting that complicates finding one optimal
solution, by covering broad ranges of values in our simulations, the decision to address a
receptor with higher or lower affinity can be made more rational.
We focused our investigations on the binding and internalization of low- to medium-
sized proteins that reach the target cells through active targeting. For that reason, our
model does not apply to delivery by the enhanced permeability and retention (EPR) effect,
which describes the passive accumulation of large entities, e.g., nanoparticles, in tumor
tissue due to a high local microvascular permeability and a poor lymphatic clearance [61].
However, for delivery by the EPR effect, the incorporation of modalities for active targeting
has only limited added value [62].
Our analyses demonstrate the promise of two strategies to mitigate the effect of the
binding-site barrier: optimizing the affinity towards the cell surface receptor and enzymatic
target modulation or targeted protein degradation (Figure 5G).
Optimizing the affinity towards cell surface receptors was identified as an approach
that could facilitate overcoming the binding-site barrier in a straightforward manner.
Importantly, affinity optimization is not synonymous with achieving as high an affinity as
possible. The findings hold for both tumors exhibiting convection and those that do not.
Cytosolic delivery of enzymes that inactivate oncogenes was recently demonstrated
through the diphtheria toxin-mediated delivery of an enzyme that inactivates wild-type and
mutant RAS [8]. The kcat of the RAS-cleaving enzyme that was used was 2.35 min−1 [63],
and is on the high end of the range of catalytic rates that were simulated by us (Figure 5A),
emphasizing that this particular approach is indeed very powerful. While tumor growth in-
hibition in vivo was achieved, challenges associated with full tumor penetration were iden-
tified that contributed to suboptimal therapeutic effects. Targeted protein degradation, as a
more generic approach for intracellular protein depletion, also exhibits great potency and
is rapidly moving towards clinical application. Although current agents to trigger targeted
protein degradation are mostly small molecule-based rather than protein-based [64–66], a
monobody binder targeting the Lck tyrosine kinase fused to von Hippel-Lindau (VHL),
a substrate receptor of the Cullin2-E3 ubiquitin ligase complex, has recently been shown
to mediate targeted protein degradation in vitro upon cytosolic delivery [39]. Notwith-
standing its potential, the high potency of targeted protein degradation or enzymatic
inactivation means that off-target delivery could prove more toxic at lower concentra-
tions (see Figure 5A,B), which emphasizes the necessity to place great importance on the
specificity of the targeting approach.
A better quantitative understanding of in vivo protein delivery has the potential
to act synergistically with a better quantitative knowledge of how many proteins are
necessary to exert a specific effect. This can range from targeted protein degradation
of highly overexpressed anti-apoptotic proteins in cancer cells or senescent cells, e.g.,
members of the BCL-2 protein family [67,68], to the delivery of transcription factors over
several days for in vivo reprogramming efforts, as was recently accomplished using an
mRNA-based approach [69]. Given the immunogenic risks associated with long-term
therapy, application areas beyond cancer in which transient administration is sufficient
are particularly promising, especially those where partial effectivity already gives rise to
substantial therapeutic effect. For example, by interfering with signaling pathways that
mediate the survival of senescent cells, a short-term protein-based approach to interfere
with these pathways may remove a fraction of the senescent cells, which is already expected
to yield multiple health-related benefits [70].
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Limitations and Future Perspectives
A limitation in our model is that surface charge of the delivered proteins has not
been taken into account. Surface charge has been shown to affect both the permeability
and interstitial diffusivity of macromolecules and nanoparticles. and this effect has been
attributed to interactions with the negatively charged basement membranes and ECM,
respectively [71–73]. Our reliance on data from neutral (i.e., non-charged) dextrans for
some parameters, for reasons of availability, means that the extrapolation towards proteins
with very different charge characteristics has to be performed with caution. However, upon
the availability of better-suited data for proteins with specific charges, these data can be
easily implemented in our model.
For our analyses, we chose a shorter plasma half-life for the therapeutic proteins than
what is common for IgG antibodies, because for cytosolic delivery, full-length antibodies
are an unlikely choice and antibodies also show only poor tissue penetration [16]. Never-
theless, for non-IgG proteins, plasma half-lives can also now be engineered to a large extent;
for example, through the inclusion of Fc segments [74] or by fusion to albumin-binding
domains to exploit FcRn receptors [75,76]. The presented model has been employed here
to extract general principles but should be refined towards protein engineering approaches
for specific applications. This can be achieved through the implementation of more detailed
and context-relevant experimental data obtained from in vivo studies and studies with mi-
crofluidic models. Experimental studies can refine the model and provide better estimates
of plasma and intracellular half-life, the approach utilized for mediating endosomal escape,
interstitial diffusivities, surface receptor internalization as a function of the targeting agent,
ubiquitination rates, and microvascular permeabilities. When these values are unknown, a
broad range of values can be tested to investigate the sensitivity towards there parameters.
This would help to understand the relevance of measuring and/or optimizing these values.
At present, the model also does not recapitulate the complexity of tumor vasculature
in vivo. However, because the aim of the model is to understand extravasation from the
vasculature, tissue penetration, and entry into cells in the direct vicinity of a capillary, we
do not consider this simplification a significant limitation. Finally, through incorporating
specific rates of transcytosis through receptors such as transferrin or insulin receptors,
which are often used for delivery across the blood–brain barrier [77,78], our model can also
be employed to simulate delivery to the brain or other tissues in which transcytosis is the
main mode of transport.
In conclusion, we have shown that the “high-hanging fruit” of proteins that exert their
therapeutic effect inside cells is well within reach of the protein engineering approaches that
are currently being pursued. Nevertheless, the proper engineering of their characteristics
will be crucial, and models such as the one presented here will guide this way.
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